William Shrader

Company: AcureX Therapeutics

Job title: Cofounder & Chief Scientific Officer

Seminars:

Discovering a Novel Mechanism Underlying LRRK2 Kinase Activity in Genetic & Sporadic Parkinson’s Disease Populations 12:00 pm

Leveraging patient-derived cell and animal model systems to investigate how 15-Lipoxygenase regulates LRRK2 kinase hyperactivity in PD Highlighting the potential of 15-Lipoxygenase inhibitors as a novel therapeutic approach to safely modify LRRK2 kinase activity and treat PDRead more

day: Conference Day One - Track One